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Clinical whole-body skin examination reduces the incidence of thick 
melanomas. 
ABSTRACT 
Survival from melanoma is strongly related to tumour thickness, thus earlier 
diagnosis has the potential to reduce mortality from this disease.  However, in the 
absence of conclusive evidence that clinical skin examination reduces mortality, 
evidence-based assessments do not recommend population screening.  We aimed 
to assess whether clinical whole-body skin examination is associated with a reduced 
incidence of thick melanoma and also whether screening is associated with an 
increased incidence of thin lesions (possible overdiagnosis). 
A population-based case-control study of all Queensland residents aged 20-75 years 
with a histologically confirmed first primary invasive cutaneous melanoma diagnosed 
between January 2000 and December 2003.  Telephone interviews were completed 
by 3,762 eligible cases (78.0%) and 3,824 eligible controls (50.4%) 
Whole-body clinical skin examination in the three years before diagnosis was 
associated with a 14% lower risk of being diagnosed with a thick melanoma 
(>0.75mm) (OR= 0.86, 95% CI=0.75, 0.98).  Risk decreased for melanomas of 
increasing thickness:  the risk of being diagnosed with a melanoma 0.76-1.49mm 
was reduced by 7% (OR=0.93, 95% CI 0.79, 1.10), by 17% for melanomas 1.50-
2.99mm (OR=0.83, 95% CI=0.65, 1.05) and by 40% for melanomas ≥3mm 
(OR=0.60, 95% CI=0.43, 0.83). Screening was associated with a 38% higher risk of 
being diagnosed with a thin invasive melanoma (≤0.75mm) (OR=1.38, 95% CI=1.22, 
1.56).   
This is the strongest evidence to date that whole-body clinical skin examination 
reduces the incidence of thick melanoma.  Because survival from melanoma is 
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strongly related to tumour thickness, these results suggest that screening would 
reduce melanoma mortality.  
INTRODUCTION  
While the incidence of melanoma has increased dramatically in white-skinned 
populations throughout the world over past decades,1-3 this has not been matched by 
a corresponding increase in mortality.1, 2  Most of the increase in incidence has been 
in thin lesions1, 2 due at least in part to increased awareness and improved 
diagnosis.  Survival following treatment is related strongly to the thickness, or depth 
of invasion, of the tumour at diagnosis,4, 5 with five-year survival following tumour 
excision ranging from 95% for lesions ≤1.00mm to as low as 45% for lesions 
>4.00mm.4  Thus, overall case fatality rates have improved2, 6 as the proportion of 
thin lesions has increased.1, 7  As most melanoma mortality occurs in patients 
diagnosed with lesions thicker than 1mm (unpublished data, Queensland Cancer 
Registry), improvements in earlier diagnosis, if accompanied by a corresponding 
reduction in the incidence of thick lesions, have the potential to reduce deaths from 
this disease.  
 
One method that may improve earlier diagnosis is skin screening, either by skin self-
examination or clinical skin examination by a doctor.  For self-examination, a case-
control study from the United States showed a significantly reduced mortality 
associated with ever having conducted skin self-examination, but also an 
unexpected reduction in melanoma incidence.8  No studies have examined the 
question of whether screening by a doctor would reduce mortality from melanoma. 
We found that melanomas detected by doctors were more likely to be thin 
(<0.75mm) than those detected by the patient themselves or by their partner or 
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friends,9 suggesting that screening by a doctor may be of benefit.  However, there is 
no conclusive evidence that self-screening or screening by a doctor will reduce 
melanoma mortality and evidence-based assessments have concluded that there is 
insufficient evidence to recommend either for or against routine screening for 
melanoma.10, 11   Nevertheless, recent population surveys in Queensland have 
shown that approximately 40% of adults aged 20-75 have had at least one whole-
body skin screening examination by a doctor in their lifetime and 20% have had one 
in the past 12 months,12 26% have practiced whole-body skin self-examination in the 
past 12 months,13 and that the overall prevalence of skin screening is increasing 
(Youl, unpublished data14), at substantial cost to the health system.  The rapid 
increase in the diagnosis of thin melanomas also raises the question of whether 
increased surveillance, including screening, leads to the diagnosis of thin melanoma 
which would not progress (overdiagnosis).15-17  The most conclusive evaluative study 
of screening is a randomised trial with mortality as the endpoint.  However, while 
such a trial has been planned and piloted,18 the cost of the whole trial has proved to 
be prohibitive .   
 
We conducted a population-based case-control study to examine the association 
between whole-body skin screening by a doctor and thickness of melanoma at 
diagnosis.  The objectives were to assess if such screening is associated with a 
reduced incidence of thick melanoma, which would be consistent with an ultimate 
mortality benefit, and also to assess if screening is associated with an increased 




Queensland residents aged between 20 and 75 years diagnosed with histologically 
confirmed first primary invasive cutaneous melanoma (not including acral lentiginous 
melanoma) between 1 January 2000 and 31 December 2003 were eligible as cases. 
During this period, 94.1% of all melanomas diagnosed in Queensland were within 
this age group. All patients with melanoma of 0.75mm or greater thickness were 
selected. For convenience, these are referred to throughout this manuscript as “thick 
melanomas”. To improve sampling efficiency and reduce cost, a random sample of 
60% of patients with thinner invasive melanoma (<0.75mm) were selected. Patients 
with non-cutaneous melanoma, metastatic disease with unknown primary, a 
confirmed previous melanoma or a melanoma with unknown thickness were 
excluded from the sampling frame. In situ melanomas were not included. For the 
small number of patients simultaneously diagnosed with more than one melanoma, 
the thickest melanoma was taken as the relevant lesion for the purpose of this study. 
Eligible patients were identified from the population-based Queensland Cancer 
Registry, to which cancer notifications have been a legal requirement since 1982. 
Letters explaining the study and seeking permission to contact the patient were sent 
to all treating doctors. Non-responding doctors were telephoned after one week. 
After permission was obtained, patients were invited by letter to participate. 
 
Control ascertainment 
Potential controls were selected from the Queensland Electoral Roll using stratified 
random sampling, based on 5-year age groups and sex distribution of the melanoma 
cases as determined from the Queensland Cancer Registry. Letters explaining the 
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study and consent forms were sent by mail, with follow-up consisting of two further 
mail outs and two reminder telephone calls as necessary. Persons with a confirmed 
diagnosis of melanoma were replaced.  
 
Data collection 
Information on screening history, melanoma risk factors and demographics was 
collected from cases and controls using computer assisted telephone interviews. 
This structured interview was preceded by sending the respondent pictorial and 
other material to assist with the assessment of freckling, naevi and other items. The 
core interview had been developed and extensively piloted in a previous study in 
Queensland.18 
 
Screening history: Information was collected from both cases and controls on self-
screening, screening by partners and other lay people, and screening by a doctor, 
referred to here as clinical skin examination. Screening history was collected only up 
to the point of first awareness of the presenting sign or symptom of melanoma in 
cases, and an equivalent “reference date” in controls. Reference dates for controls 
were based on the distribution of time between the date of first awareness of the 
presenting sign or symptom of melanoma and the date of interview of the cases. 
Within this distribution, controls were allocated reference dates randomly, such that 
the distribution of time between reference date and interview was the same as for 
cases. 
 
Clinical skin examination (CSE) was determined by asking: “During the last 3 years 
before [you first believed something was wrong (cases) / reference date (controls)], 
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had a doctor deliberately checked all or nearly all of your whole body for the early 
signs of skin cancer?”  For cases, this clinical skin examination did not include the 
initial examination by a doctor as part of the diagnostic process, unless this was a 
whole-body clinical skin examination of an asymptomatic patient, i.e., a skin 
screening examination. The validity of self-reports of clinical skin examination was 
quantified in a separate study.19  
 
Melanoma risk factors: Many factors have been related to melanoma risk, but 
multivariate models based on the analyses of case-control studies in several 
countries show a reasonably small number of critical variables.20, 21 Risk factors 
assessed in this study as potential confounders were: ethnicity (recoded to UK, 
European and Other); natural hair colour at age 21 (blonde/red , black/brown); eye 
colour (blue/grey/green/hazel, black/brown); colour of skin before tanning (very 
fair/fair, olive/brown/asian); tendency to burn when exposed to sun for an hour 
without protection (sunburn, no sunburn); degree of freckling, based on previously 
sent pictorial prompts (none/few, many); number of moles on the back (none, 1-10, 
11-30, 31-50, 50 or more); childhood sunburn experience (never, up to 10 times, 
more than 10 times) and age first arrived in Australia (born in Australia, 1-19 years, 
20-39 years, 40-75 years). Average sun exposure during the respondent’s lifetime 
was calculated and categorized based on the respondent’s recollection of the 
amount of time generally spent outside during specific periods in their life (light <400 
hrs/yr, moderate 400-599 hrs/yr, heavy 600-799 hrs/yr, very heavy 800 hrs/yr and 
more). Respondents were also asked whether they have blood relatives with a 
history of melanoma (yes/no) or blood relatives with a history of non-melanoma skin 
cancers (yes/no). Respondents were also asked whether they had ever been 
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diagnosed with other sorts of skin cancer (yes/no), and if they had ever had a mole 
removed from their skin (yes/no).  
 
Remoteness of residence, based on geographical area of residence, was assessed 
using the Accessibility/Remoteness Index of Australia (ARIA) classification,22 with 
the categories collapsed to “Highly accessible” (Capital City), Moderately 
Accessible/Accessible” (Other urban/rural) and “Remote/Very Remote” (Remote). 
 
Demographics: Basic demographic data included sex, age (ten year age groups from 
20-29 to 70 years and over), education (Primary, Junior, Senior and above), current 
employment status (full-time, part-time, not working, retired) and current marital 
status (married/partner, separated/divorced/widowed/never married). 
 
Response rates for controls 
The total number of potential controls selected for this study was 7,787. Of these, 
193 were found to be ineligible (166 had a melanoma diagnosis and 27 were 
deceased). Of the 7,594 eligible participants, consent was obtained from 3,972 
(52.3%). Of the remainder, 2,053 (27.0%) refused, 1,203 (15.8%) were unable to be 
contacted and 366 (4.8%) were contacted but did not reply. Interviews were 
completed by 3,824 (50.4%) control participants.   
 
Among the eligible potential controls, females were more likely to participate than 
males (54.1% of females and 51.1% of males, p=0.0087) and the average age of 
respondents was higher than non-respondents (53.7 years and 50.5 years 
respectively, p<0.0001).  There was little difference in the rate of participation for 
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controls who lived in and around the state capital versus those in more regional and 
rural parts of the state (53.1% and 51.4%, p=0.17).  
 
Response rates for cases 
We identified 4,839 potentially eligible cases, of whom 15 were deceased. Of the 
4,824 eligible cases, consent was obtained for 3,877 (80.4%).  Among the 
remainder, doctor’s consent was not obtained for 325 (6.7%), 369 (7.6%) refused, 
200 (4.1%) were contacted but did not reply and 53 (1.1%) were unable to be 
contacted (no current address or telephone number).  Interviews were completed by 
3,762 (78.0%) eligible cases.    
 
Among the eligible cases, females were significantly more likely to participate than 
males (82.7% compared with 78.7%, p<0.01) and participation was lower among 
patients with thicker tumours (81.8% participation for those with tumours ≤0.75mm; 
82.7% for tumours 0.76-1.49mm; 76.0% for tumours 1.5-2.99mm; 74.2% for tumours 
≥3.00mm; p<0.001).  There was little difference in participation according to mean 




The test-retest reliability of the questionnaire was assessed by re-interviewing 164 
cases and 104 controls one to three months after their first interview. We used 
Cohen’s Kappa statistic23 to assess the agreement between the two interviews. 
There was good agreement for the question on clinical skin examination for both 
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cases and controls (K (cases)=0.714, 95%CI=0.60, 0.83; K (controls)=0.785, 
95%CI=0.66, 0.91), with concordance values of 87% and 90% respectively. 
 
Additional data from the Queensland Cancer Registry 
Interview data for melanoma cases were combined with pathology data held by the 
Queensland Cancer Registry including tumour thickness, histology and level of 
invasion.  Although the current recommended cut points within the T classification for 
melanoma thickness are 1mm, 2mm and 4mm,4 this was only officially implemented 
in 2003.  This study, which commenced data collection in January 2000, was 
designed prior to the revised classification being released. Therefore the selection 
and stratification of cases in this study, and subsequent analyses, were based on the 
previous thickness classification24, 25 which uses cut points of 0.75mm, 1.5mm and 
3mm. The presentation of our results by thickness in this paper reflects this. 
 
Statistical analysis 
In this analysis, self-reported screening histories for patients with thick (>0.75mm) 
and thin (≤0.75) melanoma were each compared separately to population controls to 
calculate the associations between screening by a doctor and the risk of thick 
melanoma, and between screening by a doctor and the risk of thin melanoma.  If 
clinical skin examination does reduce the incidence of thick melanoma by allowing it 
to be diagnosed while it is more superficial, the odds ratio for thick melanomas would 
be less than one.  If clinical skin examination increases the frequency of thin 
melanomas, then the odds ratio for thin melanomas would be greater than one. 
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Potential confounders included those factors listed above related to melanoma risk, 
and demographic factors potentially related to the experience of screening.  As a 
previous diagnosis of skin cancer or having had a mole removed may have been the 
reason for clinical skin examination, even if not in the causal pathway, we left these 
variables out of the list of potential confounders.26  Initially a polytomous model 
containing all the potential confounders was fitted, using the case (4 levels of 
thickness) / control (1 level) status as the outcome variable. This model was then 
refined by stepwise removal of variables with no statistically significant association 
with the outcome measure (in this instance taken to be when p>0.20, based on the 
likelihood ratio test) after adjusting for the other variables in the model. 
 
Adjusted odds ratios and 95% confidence intervals were calculated from the 
parameter estimates of the final polytomous regression model. 
 
The total number of subjects deleted from the final regression model due to missing 
values was 259 (3.4% of all subjects). This proportion of excluded subjects was 
slightly higher for cases (4.0%) than for controls (2.8%). 
 
To assess whether there was evidence of a linear association between tumour 
thickness and clinical skin examination, we used a linear regression model for cases 
only with the log-transformed thickness as the outcome variable, adjusting for the 
same potential confounders as for the main analysis. 
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We repeated the main analysis, restricting it to only those respondents who had 
reported no previous history of skin cancer, and having had no moles previously 
removed.  
 
Since the original study design and sampling methodology were based on the 
Breslow staging system, we used those categories for the primary analysis. However 
we  repeated the analysis using thickness categories based on the current AJCC 
staging system27, introduced after the current study was designed and sampling was 
underway.  Because relatively few melanomas were greater than 4.0mm thickness, 
all melanomas greater than 2.0mm thickness were grouped together in this analysis.   
 
To estimate the number of deaths that might be prevented by clinical screening in 
our sample, we estimated the average 5- and 10-year survival for screened and 
unscreened cases.  We calculated thickness-specific 5- and 10-year cause-specific 
survival for all melanoma patients diagnosed between 1990 and 2003 [source: 
Queensland Cancer Registry] and applied these estimates to the number of 
screened and unscreened cases in each thickness category in our sample.  We then 
compared the expected mortality within 5 and 10 years between the two groups.  
 
All analysis was conducted using SAS 9.1.28 
 
Ethical approval for the study was granted by the Behavioral and Social Sciences 
Ethical Review Committee of the University of Queensland. Informed consent was 
obtained from each study participant.
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RESULTS 
The final sample for analysis was 3,762 cases and 3,824 controls. The proportion of 
cases who reported having had a clinical skin examination within the 3 years before 
the melanoma was first noticed (35.3%) was higher than that for controls (28.3%; 
based on the reference date). For the cases, the percentage who had a clinical skin 
examination within 3 years of diagnosis was inversely associated with thickness (χ2 
test for trend=44.37, df=1, p<0.001): 38.7% among those with melanomas ≤0.75mm 
thick, 30.3% among those with melanomas between 0.76 and 1.49mm, 28.2% for 
those with melanomas between 1.50 and 2.99mm, and 22.5% for people with 
melanomas ≥3mm thick (Table 1). 
 
Among the controls, we found that older respondents, those with higher education, 
those who were married, had olive or brown skin colour, had an increased number of 
moles on the back, increased number of childhood sunburn experiences, lived in the 
south east corner of Queensland (capital city), had a family history of melanoma, a 
family history of nonmelanoma skin cancer, a previous diagnosis of skin cancer or 
had a mole removed were all independently more likely to report having had a 
clinical skin examination in the three years prior to the reference date (Table 2). 
  
The final list of potential confounders resulting from the model building process 
comprised sex, age, education, employment status, marital status, eye colour, hair 
colour, skin colour, degree of freckling, number of moles on back, age at first arrival 
in Australia, average lifetime sun exposure, family history of melanoma (blood 
relatives), family history of non-melanoma skin cancer (blood relatives), and ethnic 
status.  
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After adjustment for these variables, whole-body clinical skin examination in the 
three years before melanoma diagnosis was associated with a 14% lower risk of 
being diagnosed with thick melanoma (>0.75mm) (OR= 0.86, 95% CI=0.75, 0.98), 
with the risk decreasing with increasing thickness (Table 1).   The risk of being 
diagnosed with a melanoma 0.76-1.49mm was reduced by 7%, (OR=0.93, 95% CI 
0.79, 1.10), by 17% for melanomas 1.50-2.99mm (OR=0.83, 95% CI=0.66, 1.05) and 
by 40% for melanomas ≥3mm in diameter (OR=0.60, 95% CI=0.43, 0.83) (Table 1). 
Screening was associated with a 38% higher risk of being diagnosed with a thin 
melanoma (≤0.75mm) (OR=1.38, 95% CI=1.22, 1.56).  There was a significant 
inverse linear association between melanoma thickness and having had a clinical 
skin examination – the average thickness was 18% less (95% CI =13%, 22%) for 
those who had had a clinical skin examination (β=-0.196, df=1, p<0.001) 
 
Results were similar and in the same direction within strata defined by sex and 
separately by age (20-49 years, 50-74 years (Table 3).  Consistent with this, an 
additional model (full results not shown) including the interaction terms of clinical skin 
examination and sex and clinical skin examination and age found no statistically 
significant interaction (χ2=4.83, df=4, p=0.31 and χ2=20.11, df=20, p=0.45 
respectively). 
 
Similar results were observed when we limited the analysis to those people who 
reported no previous history of skin cancer, and reported they had not had a mole 
removed (Table 1). The main difference between the full analysis and this reduced 
analysis was that in the reduced analysis, the association was slightly stronger for 
melanomas 1.50-2.99mm and ≥3.00mm (Table 1). 
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We repeated the analysis using a modified definition of exposure.  Specifically, we 
did not include in our definition of “whole-body clinical skin examination in the past 
three years” those examinations at which the melanoma was first detected (Table 4). 
After adjustment for potential confounders in this analysis, there was no longer any 
association with clinical skin examination and thin melanomas.  For melanomas 
thicker than 0.75 mm, the trend of decreasing odds ratios with increasing thickness 
remained.  In this analysis, the risk of melanoma greater than 3.00mm was reduced 
by 45% (OR=0.55, 95% CI=0.39, 0.77). 
 
Results were similar and in the same direction when the analysis was repeated using 
categories based on the current AJCC staging system.  After adjustment, whole-
body clinical skin examination in the three years before melanoma diagnosis was 
associated with an 18% lower risk of being diagnosed with thick melanoma 
(>1.00mm) (OR= 0.82, 95% CI=0.69,  0.99), with the risk decreasing with increasing 
thickness.    The risk of being diagnosed with a melanoma 1.01-2.00mm was 
reduced by 13%, (OR=0.87, 95% CI 0.70, 1.09) and by 27% for melanomas 
>2.00mm (OR=0.73, 95% CI=0.55, 0.98).  Screening was associated with a 32% 
higher risk of being diagnosed with a thin invasive melanoma (≤1.00mm) (OR=1.32, 
95% CI=1.18, 1.47).   
 
After applying the thickness-specific Queensland cause-specific survival estimates to 
the thickness distribution of the screened and unscreened cases in our sample, we 
estimated that the average 5- and 10-year survival for unscreened cases would be 
93.8% and 90.4%, and for screened cases it would be 95.5% and 92.6% 
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respectively. Adjusting for the differences in numbers of screened and unscreened 
cases, we estimated that compared to unscreened cases, the screened cases would 
have 26% fewer melanoma deaths within 5 years and 23% fewer deaths within 10 
years of diagnosis. 
  
DISCUSSION  
Our results indicate that whole-body clinical skin examination in the three years prior 
to melanoma diagnosis is associated with a 14% reduction in the incidence of all 
thick melanoma (>0.75mm), including a 7% reduction in the incidence of melanoma 
0.76-1.49mm thick, a 16% reduction in the incidence of melanoma 1.5-2.99mm thick, 
and a 40% reduction in the incidence of melanoma ≥3.00mm thick. Overall, there 
was a regular and significant trend towards lower incidence of melanomas of 
increasing thickness.   
 
Could this association be due to bias?  The comparison of screening histories 
between melanoma patients and population controls is open to the problem of recall 
bias, common to all similar retrospective study designs.   We asked about screening 
histories using a standard, well-tested and reliable question, which we have found 
previously to have high validity when compared against medical records,19 with no 
detectable difference in accuracy of recall between melanoma patients and others.  
Even if it were the case that recently diagnosed melanoma patients have different 
recall abilities than healthy controls, there is no reason to suggest that patients with 
different thicknesses of melanoma would show differential recall, therefore it is 
unlikely that recall bias would have produced the trend of reducing odds ratios with 
increasing melanoma thickness that was observed.    
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It is also possible that if screening does result in earlier diagnosis, cases who die or 
are seriously ill relatively soon after diagnosis are those least likely to have been 
screened.29  These are also likely to have been the thicker cases and failure to 
interview these cases may bias the association between screening and thick 
melanoma towards the null. To minimise the potential for this selection bias, we 
interviewed cases as soon as possible after diagnosis, with a median time between 
diagnosis and interview for cases of 5 months, and 8 months (between reference 
date and interview) for controls.  Nevertheless, there was a significant inverse 
association between participation rates and thickness which may have resulted in 
our underestimating the association with screening.  There is also the possibility of 
selection bias for the controls; if there were a higher prevalence of screening in the 
51% of responding eligible controls than in non-respondents, the results would tend 
to underestimate the odds ratio for the association between screening and diagnosis 
of melanoma.  While this is possible, it is difficult to see how this potential source of 
bias would have resulted in the opposite associations with screening that we 
observed for thin and thick melanomas and the inverse trend observed within thick 
melanomas. 
 
Confounding, by factors which are associated with both the experience of screening 
and also with the diagnosis of melanoma of a particular depth, is another possible 
explanation for these results. We controlled for known melanoma risk factors 
demonstrated to be associated with screening participation.  We avoided including in 
the model those factors which may be intermediate in the causal pathway between 
screening and melanoma diagnosis by depth, such as previous removal of lesions.      
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These results are consistent with the hypothesis that clinical skin examination results 
in earlier detection and treatment of tumours which would otherwise have been 
diagnosed later, leading to a reduction in the incidence of thick melanoma.  Would 
such a reduction in the incidence of thick melanoma associated with screening mean 
that screening would result in a reduction in melanoma mortality?  Advancing the 
diagnosis is a necessary condition for a reduction in mortality but it is not sufficient.  
Screening is more likely to detect slowly growing lesions than fast growing lesions 
(length bias) and as a consequence is more likely to detect lesions that would not kill 
the person in their lifetime.  Additionally, if lesions that would have been diagnosed 
as thick lesions in the normal course of events are detected by screening 
chronologically earlier but after they had metastasised, there would be little impact 
on eventual mortality.  When we applied the expected five- and ten-year survival 
estimates for Queensland by thickness to the thickness distribution of the screened 
and unscreened cases, we estimated that, in the absence of these biases, screening 
may reduce fatality by at least 20%.  However, a randomised trial with mortality as 
the outcome is the only means of actually determining the extent to which screening 
might reduce mortality.    
  
There are two possible explanations for the observed 38% increase in thin 
(≤0.75mm) melanoma associated with whole-body clinical skin examination.   It 
cannot be assumed that all thin melanomas removed would  have progressed to 
invasive disease if left alone.   Some of the increase in the incidence of thin lesions 
may be due to the diagnosis of non-progressive lesions, i.e. lesions that have no 
potential for metastasis.15-17  This potential over-diagnosis would have no impact on 
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the future incidence of thick lesions.   However, given the observed reduction in the 
incidence of thick lesions, some of the increase in thin lesions is likely to be due to a 
shift from thick to thin melanoma as a result of screening. It is not possible to 
estimate the relative size of these two effects from cross-sectional data.     
 
Population-based surveys indicate that whole-body clinical skin screening has 
increased in Queensland in recent years and with increasing awareness and the 
rapid increase in skin cancer screening clinics in Queensland,30 this is likely to 
continue.  It is likely that this population has not reached a steady state in regard to 
the prevalence of skin screening. Therefore, one would expect that the immediate 
increase in incidence of thin lesions that would be seen at the start of a screening 
program would not yet have become apparent in a matching reduction in thick 
lesions.   The data presented here are consistent with there having already been 
some shift from thick to thin lesions in our sample due to earlier diagnosis as the 
result of whole-body skin examination.  
 
These results provide the strongest evidence to date that whole-body clinical skin 
examination reduces the incidence of thick melanoma.  Because survival from 
melanoma is strongly related to melanoma thickness and most melanoma mortality 
occurs in patients diagnosed with lesions thicker than 1mm, these results suggest 
that screening would reduce melanoma mortality.  
 
Finally, it is important to consider whether the evidence presented here is sufficient 
to recommend population-based skin screening.  The decision to introduce a 
population-based screening program is one that is based both on scientific evidence 
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of benefit and also a careful examination of costs and hazards.  The current study 
provides the best evidence to date and, in the absence of a randomised trial, the 
best evidence we are likely to achieve for some time that skin screening by a doctor 
will reduce mortality from melanoma.  It does not provide information on costs either 
to the patient or to the health system.  Therefore, the decision whether or not to 
undergo skin screening is one that should remain an individual one to be discussed 
between the patient and his or her doctor in the light of this new evidence that skin 
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Table 1: Odds ratios for (self-reported) clinical skin examination in 3 years prior to first noticing something wrong: Results of 
polytomous regression model 
Control / Thickness 
Had a doctor skin 
screen in last 3 
years? 
 
Unadjusted 1 Adjusted 2 
“De novo screening” (adjusted) 
3 
Odds Ratio 4 p-value Odds Ratio 4 
p-
value 
Odds Ratio 4 p-value 
        




1.38 [1.22 , 
1.56] 
<0.001 1.35 [1.12 , 1.63] 0.002 




0.93 [0.79 , 
1.10] 
0.393 0.93 [0.73 , 1.19] 0.572 




0.83 [0.66 , 
1.05] 
0.128 0.67 [0.45 , 1.00] 0.047 




0.60 [0.43 , 
0.83] 
0.002 0.56 [0.32 , 0.97] 0.037 
Controls [n=3824] 1083 (28.3%) 1.00  1.00  1.00  
26 
 
1. Results of polytomous regression model with melanoma thickness as the outcome variable (4 thickness levels, and the control 
group) and reported CSE as the independent variable, and including age group and sex to account for the frequency matching of 
cases with controls. 
2. Same as (1), except also adjusted for education, employment status, marital status, eye colour, hair colour, skin colour, degree of 
freckling, number of moles on back, age first arrival in Australia, average lifetime sun exposure, family history of melanoma (blood 
relatives), family history of non-melanoma skin cancer (blood relatives) and ethnic status. 
3. Same as (2), except only includes respondents who have not had a mole previously removed nor a previous diagnosis of skin 
cancer (n=4135) 
4. Controls are the reference category 
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Table 2: Factors associated with having had a clinical skin examination (CSE) within 
the three years prior to the reference date among the 3,824 control participants only 





 Male (n = 2,203) 










 20 – 29 (n=184) 
 30 – 39 (n=445) 
 40 – 49 (n=780) 
 50 – 59 (n=1002) 
 60 – 69 (n=878) 


















 Years 11-12 & upwards (n = 2,405) 
 Years 7 to 10 (n = 1,129) 












 Full-time (n=1630) 
 Part-time (n=559) 
 Not working (n=473) 













Marital Status    
28 
 Married/partner (n=3032) 








 Blue/Grey/Green/Hazel (n=2918) 










 Brown/black (n = 3,023)  










 Olive/brown (n = 774) 









Tendency to burn after sun exposure 
 No sunburn (n = 265) 









Degree of freckling 
 None/Few (n = 3295) 









Number of moles on back 
 None (n=1038) 
 1-10 (n=1955) 
 11-30 (n=590) 
 31-50 (n=116) 















Childhood sunburn experience    
29 
 Never (n=545) 
 Up to 10 times (n=2459) 








Age first arrived in Australia 
 Born in Australia (n=3258) 
 1-19 years (n=221) 
 20-39 years (n=273) 













Average lifetime sun exposure 
 Light (n = 403)) 
 Moderate (n=1123) 
 Heavy (n=1222) 












Remoteness of residence 
 Capital city (n=2706) 
 Other urban/rural (n=1003) 











Family history of melanoma (blood relatives) 
 Yes (n=553) 









Family history of non-melanoma skin cancer (blood 
relatives) 
 Yes (n=826) 









Ethnic status    
30 
 UK (n=2540) 
 European (n=361) 








Previous diagnosis of skin cancer 
 Yes (n=734) 









Ever had a mole removed 
 Yes (n=982) 











† Adjusted odds ratios calculated from the parameter estimates of a logistic 
regression model with the p values from the likelihood ratio chi-squared test. 
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Table 3: Odds ratios for clinical skin examination (within 3 years) showing adjusted odds ratios from the main model stratified by 
sex and age group.  
 
 0.01-0.75mm 0.76-1.49mm 1.50-2.99mm 3.00mm + 
Males 1.54 [1.31 , 1.82] ** 0.96 [0.78 , 1.19] 0.85 [0.63 , 1.15] 0.62 [0.42 , 0.91] * 
Females 1.20 [0.99 , 1.45] 0.90 [0.70 , 1.16] 0.79 [0.54 , 1.16] 0.55 [0.29 , 1.03] 
20-49 years 1 1.32 [1.08 , 1.62] * 0.98 [0.76 , 1.27] 0.67 [0.41 , 1.07]  0.48 [0.22 , 1.06] 
50-74 years 1.43 [1.22 , 1.67] ** 0.91 [0.74 , 1.12] 0.90 [0.68 , 1.18] 0.62 [0.43 , 0.89] * 
 
Note: *: p<0.05; **: p<0.01 




Table 4: Odds ratios for (self-reported) clinical skin examination in 3 years prior to first noticing something wrong: Results of 
polytomous regression model (excluding asymptomatic clinical skin examinations carried out at the time of first detection). 
Control / Thickness 
Had a doctor skin 
screen in last 3 
years? 
 
Unadjusted 1 Adjusted 2 
“De novo screening” (adjusted) 
3 
Odds Ratio 4 
p-
value 
Odds Ratio 4 
p-
value 
Odds Ratio 4 p-value 
        




0.95 [0.84 , 
1.08] 
0.436 0.75 [0.61 , 0.92] 0.007 




0.76 [0.65 , 
0.90] 
0.002 0.71 [0.54 , 0.92] 0.011 




0.74 [0.58 , 
0.94] 
0.013 0.60 [0.40 , 0.90] 0.013 




0.55 [0.39 , 
0.77] 
<0.001 0.52 [0.30 , 0.91] 0.023 
Controls [n=3824] 1083 (28.3%) 1.00  1.00  1.00  
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1. Results of polytomous regression model with melanoma thickness as the outcome variable (4 thickness levels, and the control 
group) and reported CSE as the independent variable , and including age group and sex to account for the frequency matching of 
cases with controls. 
2. Same as (1), except also adjusted for sex, age, education, employment status, marital status, eye colour, hair colour, skin colour, 
degree of freckling, number of moles on back, age at first arrival in Australia, average lifetime sun exposure, family history of 
melanoma (blood relatives), family history of non-melanoma skin cancer (blood relatives), and ethnic status. 
3. Same as (2), except includes only respondents who have not had a mole removed previously nor a previous diagnosis of skin 
cancer (n=4135) 
4. Controls are the reference category 
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